U.S. Markets
US FDA approves subcutaneous induction regimen for AbbVie’s (ABBV) Skyrizi for adults with moderately to severely active Crohn’s disease
StockNow breaking-news AI analysis
The breaking-news headline reports FDA approval of Skyrizi subcutaneous induction for adults with active Crohn’s disease, but supplied evidence lacks underlying approval details.
Related stocks
1 stocks
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.